Pharmaceuticals Market Research Reports & Industry Analysis

Publications found: 36,694

Sort by:

Global Keloid Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of Keloid Treatment, for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze ...

October 2018 128 pages

Global Leukemia Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of Leukemia Therapeutics, for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze ...

October 2018 128 pages

Global Pancreatic Cancer Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... display the global Pancreatic Cancer Treatment market. Chapter 1, to describe Pancreatic Cancer Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2, to analyze the top manufacturers of Pancreatic Cancer Treatment, with ...

October 2018 128 pages

Global Parkinson's Disease Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of Parkinson's Disease, for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze ...

October 2018 133 pages

Global Pulmonary Arterial Hypertension (PAH) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... the Report: This report focuses on the Pulmonary Arterial Hypertension (PAH) in global market, especially in North America, Europe and ... Chapters to deeply display the global Pulmonary Arterial Hypertension (PAH) market. Chapter 1, to describe Pulmonary Arterial Hypertension (PAH) Introduction, product scope, ...

October 2018 130 pages

Global Radiation Therapy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of Radiation Therapy, for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze ...

October 2018 135 pages

Global Retail Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of Retail Drug, for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze ...

October 2018 135 pages

Global Sexually Transmitted Disease (STD ) Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... Report: This report focuses on the Sexually Transmitted Disease (STD ) Drug in global market, especially in North America, Europe ... Chapters to deeply display the global Sexually Transmitted Disease (STD ) Drug market. Chapter 1, to describe Sexually Transmitted Disease (STD ) Drug Introduction, product scope ...

October 2018 129 pages

Global Small Cell Lung Cancer Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... Chemotherapy There are 15 Chapters to deeply display the global Small Cell Lung Cancer Treatment market. Chapter 1, to describe Small Cell Lung Cancer Treatment Introduction, product scope, market overview, market ...

October 2018 128 pages

Global Thyroid Cancer Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... display the global Thyroid Cancer Treatment market. Chapter 1, to describe Thyroid Cancer Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2, to analyze the top manufacturers of Thyroid Cancer Treatment, with ...

October 2018 137 pages

Global Neuroendocrine Carcinoma Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of Neuroendocrine Carcinoma, for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze ...

October 2018 133 pages

Global Oral Controlled Release Drug Delivery Technology Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... and application. The Dissolution Controlled Release System segment dominated the global oral controlled release drug delivery technology market in terms ... deeply display the global Oral Controlled Release Drug Delivery Technology market. Chapter 1, to describe Oral Controlled Release Drug Delivery Technology ...

October 2018 128 pages

Global Pulmonary Arterial Hypertension Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... the Report: This report focuses on the Pulmonary Arterial Hypertension Treatment in global market, especially in North America, Europe ... to deeply display the global Pulmonary Arterial Hypertension Treatment market. Chapter 1, to describe Pulmonary Arterial Hypertension Treatment Introduction, product scope, ...

October 2018 135 pages

Investigation Report on China's Omeprazole Market, 2018-2022

US$ 2,200.00

... certain growth potential in China. Topics Covered: Situation of gastric ulcer in China Sales of Omeprazole in China Competition on China's Omeprazole market Major Omeprazole manufacturers in China Prices of Omeprazole in China Prospect of China's Omeprazole market from 2018 ...

October 2018 30 pages

Investigation Report on China's Repaglinide Market, 2018-2022

US$ 2,200.00

... . Topics Covered: Situation of type 2 diabetes in China Size of China's Repaglinide market Major Repaglinide manufacturers in China Competition on China's Repaglinide market Retail prices of Repaglinide in China Prospect of China's Repaglinide market from 2018 to 2022

October 2018 30 pages

Global Life Science Tools & Reagents Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 3,480.00

... of the Report: This report focuses on the Life Science Tools & Reagents in global market, especially in North America, Europe and Asia ... are 15 Chapters to deeply display the global Life Science Tools & Reagents market. Chapter 1, to describe Life Science Tools & Reagents Introduction, product scope, market ...

October 2018 147 pages

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape Develop and ...

October 2018 112 pages

Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2018

US$ 3,500.00

... Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2018 52 pages

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H2 2018

US$ 3,500.00

... Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2018 43 pages

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Pipeline Review, H2 2018

US$ 3,500.00

... players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics development ...

October 2018 62 pages

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) development landscape Develop and ...

October 2018 62 pages

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) development ...

October 2018 38 pages

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2018

US$ 3,500.00

... players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) development ...

October 2018 102 pages

Antibiotics Market by Class (Beta Lactam & Beta Lactamase, Quinolones, Macrolides, and Others), Drug Origin (Natural, Semisynthetic, and Synthetic), Spectrum of Activity (Broad-spectrum Antibiotic and Narrow-spectrum Antibiotic), and Route of Administration (Oral, Intravenous, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

US$ 5,370.00

... allow companies to strategically plan their business moves. Antibiotics Key Market Segments: By Class Beta Lactam & Beta Lactamase Inhibitors Penicillin Cephalosporin Carbapenem Monobactam Quinolones Macrolides ...

October 2018 282 pages

Precision Medicine (Diagnostics/Therapeutics) Market Analysis Report By Application (Genetic Tests, Esoteric Tests, Pharmaceuticals, Medical Devices), By End Use, And Segment Forecasts, 2018 - 2025

US$ 5,950.00

The global precision medicine (diagnostics/therapeutics) market size is expected to reach USD 85.5 billion by 2025 at a 9.9% CAGR during the ...

October 2018 145 pages

Global Immunosuppressive Drug Market Research and Forecast, 2018-2023

US$ 3,600.00

... segments: Global immunosuppressive drug market research and analysis, by application Global immunosuppressive drug market research and analysis, by drug type THE REPORT COVERS: Comprehensive research methodology of the global immunosuppressive drug market. Immunosuppressive drug report also ...

October 2018 -

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2018

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) development landscape Develop and design ...

October 2018 80 pages

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2018

US$ 3,500.00

... players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) development ...

October 2018 69 pages

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2018

US$ 3,500.00

... Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2018 53 pages

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Review, H2 2018

US$ 3,500.00

... Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2018 73 pages

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H2 2018

US$ 3,500.00

... 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development ...

October 2018 98 pages

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2018

US$ 3,500.00

... , this report also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics development with respective active and dormant ...

October 2018 74 pages

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) development landscape Develop ...

October 2018 50 pages

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2018

US$ 3,500.00

... Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2018 61 pages

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Review, H2 2018

US$ 3,500.00

... ) and molecule type. It also reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics development with respective active and dormant ...

October 2018 58 pages

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H2 2018

US$ 3,500.00

... D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2018 72 pages

Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) development ...

October 2018 36 pages

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) development ...

October 2018 62 pages

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2018

US$ 3,500.00

... Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2018 41 pages

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) development landscape Develop ...

October 2018 109 pages

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2018

US$ 3,500.00

... Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2018 54 pages

Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3) - Pipeline Review, H2 2018

US$ 3,500.00

... this report also reviews key players involved in Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3) targeted therapeutics development with respective active and ...

October 2018 29 pages

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2018

US$ 3,500.00

... C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2018 54 pages

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H2 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) development landscape Develop and design ...

October 2018 50 pages

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2018

US$ 3,500.00

... , this report also reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics development with respective active and ...

October 2018 92 pages

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2018

US$ 3,500.00

... molecule type. It also reviews key players involved in Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics development with respective active and ...

October 2018 35 pages

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2018

US$ 3,500.00

... acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape Develop and design in-licensing and ...

October 2018 123 pages

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) development ...

October 2018 62 pages

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2018

US$ 3,500.00

... Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2018 47 pages

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) development landscape ...

October 2018 48 pages

Filters

Clear all

Price

—

Date

—

Pages

—

Offers

Discount Offer from GMD Research

Special Offer from MP Advisors

Special Offer on Therapy Class R...